TNF and hepatosplenic T-cell lymphoma: Another important aspect to consider is that Hepatosplenic T-cell lymphoma (HSTCL), though rare, is a potential risk associated with the use of tumor necrosis factor inhibitors (TNFis) in treating IBD.